RxDoctor Payments Data

Donald Maddack, DO

Family Medicine · Venice, FLNPI 1013911031

Payments from drug & device makers

$9,076in general payments, 2019–2025

Across 553 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$767
  • GSK$622
  • Novo Nordisk$611
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$9,050100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,076 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$139,117
Medicare patients
368
Services billed
2,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$71,429
MounjaroTirzepatide48$50,604
EliquisApixaban38$50,436
XareltoRivaroxaban36$34,623
JardianceEmpagliflozin15$20,605
FarxigaDapagliflozin Propanediol16$16,701
Breo ElliptaFluticasone/Vilanterol22$14,731
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,676
Tresiba Flextouch U-100Insulin Degludec14$7,317
Lisdexamfetamine Dimesylate21$4,944
DuleraMometasone/Formoterol14$4,726
VyvanseLisdexamfetamine Dimesylate12$4,522
Celecoxib35$3,085
Atorvastatin Calcium440$3,082
Metoprolol Succinate186$2,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$611$71,42938 claims
Lilly USA, LLCMounjaro$1,052$50,60448 claims
PfizerEliquis$1,229$50,43638 claims
Johnson & JohnsonXarelto$63$34,62336 claims
GSKBreo Ellipta, Trelegy Ellipta$622$24,40634 claims
Boehringer IngelheimJardiance$145$20,60515 claims
AstraZenecaFarxiga$767$16,70116 claims
MerckDulera$459$4,72614 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$147$4,52212 claims
AbbVieSynthroid$1,497$2,93130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →